ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics


ABVC BioPharma, Inc. (ABVC): $1.95

-0.06 (-2.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABVC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABVC Stock Price Chart Interactive Chart >

Price chart for ABVC

ABVC Price/Volume Stats

Current price $1.95 52-week high $11.69
Prev. close $2.01 52-week low $1.95
Day low $1.95 Volume 68,200
Day high $2.02 Avg. volume 68,785
50-day MA $2.41 Dividend yield N/A
200-day MA $2.78 Market Cap 59.10M

ABVC BioPharma, Inc. (ABVC) Company Bio


American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.


ABVC Latest News Stream


Event/Time News Detail
Loading, please wait...

ABVC Latest Social Stream


Loading social stream, please wait...

View Full ABVC Social Stream

Latest ABVC News From Around the Web

Below are the latest news stories about Abvc Biopharma Inc that investors may wish to consider to help them evaluate ABVC as an investment opportunity.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022. Principal investigators from the University of California San Francisco (“UCSF”) Medical Center and five prestigious Taiwan medi

Yahoo | February 2, 2022

ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites

Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute intended to facilitate ret

Yahoo | January 5, 2022

ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS Congress

Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world's first bio-degradable vitreous substitute, was presented by Dr. Andrew Chang, MD, Ph.D on December 11, 2021 at the 14th Asia-Pacific Vitreo-Retina Society (“APVRS”) Congress. APVRS, one of the most prestigious ophthalmology confe

Yahoo | December 22, 2021

ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award

Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its vitreous substitute intended to facilitate retina re-attachment surgery, received the 2021 National Innovation and Renewal of Diligence award from the Institute for Biotechnology and Medicine Industry (IBMI) of Taiwan. The award was presented at the Taiwan Medical Technology Exhibition on December 2, 2021 at the Taipei Nangang Exhibition Center.

Intrado Digital Media | December 15, 2021

Why ABVC BioPharma Shares Are Trading Higher On Friday?

ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms. In addition, BioKey has entered into a three-year distribution agreement with Define Biotech Co Ltd, Taiwan-based pharmaceutical marketing

Yahoo | December 10, 2021

Read More 'ABVC' Stories Here

ABVC Price Returns

1-mo -18.41%
3-mo -21.37%
6-mo -35.86%
1-year -64.55%
3-year N/A
5-year N/A
YTD -42.48%
2021 -33.53%
2020 16.70%
2019 -87.86%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5081 seconds.